Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Exclusion Criteria

• •Patients with brain metastases
• •Patients who have received or who are expected to receive any prohibited medications and therapies
• •Patients who have received CYP1A2 inducer, CYP2C9/2C19 inducer or CYP3A4 inducer medications within 30 days prior to start study treatment or are expected to receive during the first 14 days after starting the study treatment
• •Patients with a known hypersensitivity to benzodiazepines
• •Patients who have not recovered from previous anti-cancer therapies
• •Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of TKI258
• •Patients who have concurrent severe and/or uncontrolled concomitant medical conditions that could compromise participation in the study
• •Female patients who are pregnant or breast-feeding
• •Fertile males or women not willing to use highly effective methods of contraception